JUN 14, 2017 4:13 PM PDT

Identifying A Rare Autoimmune Disease at the Cellular Level

WRITTEN BY: Kara Marker

Diagnostic tests for a rare autoimmune disease called anti-phospholipid antibody syndrome (APS) are unreliable, and treatments are not sustainable long-term. However, a new discovery of the disease’s causation from the University of Geneva might alter solutions for both of these problems.

 Anti-phospholipid antibody syndrome occurs when the immune system attacks normal proteins in the blood.

APS is characterized by autoantibodies in the blood plasma that target anticoagulant proteins, leading to excessive blood clotting. Binding of these autoantibodies can occur in the blood vessels and in the placenta, with dangerous consequences such as venous thromboses, strokes, and miscarriages. APS is rare, affecting less than one percent of the population, but this condition often occurs simultaneously with lupus or rheumatoid arthritis.

Current diagnostic approaches for APS require the expertise of a hematologist, an extensive review of a patient’s medical history, and blood tests scanning for three antibodies that indicate APS: anticardiolipin, beta-2 glycoprotein I, lupus anticoagulant. However, variability, specificity, and sensitivity of these tests are not always dependable.

Treatment options for APS almost exclusively involve oral anticoagulants, but extended use raises risk of adverse side effects, especially for pregnant women.

"The current diagnostic tests use the entire protein, which reduces its specificity and leads to standardization issues,” explained Karim Brandt, a researcher from the study. “Consequently, two tests are required at an interval of 12 weeks after a thrombotic episode or following one or more miscarriages. Our new test specifically targets this pathogenic antibody, with rapid and more accurate results."

The new diagnostic approach is to be devised based upon the discovery of the precise location of anti-phospholipid antibody binding. Identifying the exact location of binding allowed scientists to study in detail how the binding occurs and its specific effects on blood clotting. They found that binding triggers the release of pro-inflammatory and pro-thrombotic factors that are the basis of the condition’s dangerous consequences. 

"Our breakthrough could also give rise to a targeted treatment that would neutralize specific pathogenic antibodies, reducing not just their actions but also the side effects associated with the current treatment,” Brandt explained. “It would involve injecting the protein motif we have identified into a patient's circulatory system so that it explicitly binds itself to the pathogenic antibody and prevents it from causing harm."

The present study was published in the journal Haematologica.

Sources: National Heart, Lung, and Blood Institute, University of Geneva

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 17, 2020
Immunology
Nervous Protein Neuromedin B May Prevent Immune Reactivity
AUG 17, 2020
Nervous Protein Neuromedin B May Prevent Immune Reactivity
A protein produced by the nervous system seems to play a role in regulating the immune system. For people with inflammat ...
SEP 17, 2020
Immunology
COVID Vaccine Works in Macaques - What about in Humans?
SEP 17, 2020
COVID Vaccine Works in Macaques - What about in Humans?
Pharmaceutical giant Pfizer, in partnership with BioNTech has reported that one of its lead vaccine candidates has shown ...
OCT 06, 2020
Immunology
COVID Triggers Abnormalities in Immune Monocytes
OCT 06, 2020
COVID Triggers Abnormalities in Immune Monocytes
University of Manchester immunologists are the first to make an interesting observation about the white blood cells of p ...
OCT 14, 2020
Immunology
Self-Healing Microcapsules Make Promising Leukemia Vaccines
OCT 14, 2020
Self-Healing Microcapsules Make Promising Leukemia Vaccines
Leukemia is a cancer affecting tissues in the body that produce blood cells, including the bone marrow and the lymphatic ...
NOV 12, 2020
Immunology
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
NOV 12, 2020
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
Nutrition is essential to health; what we eat in our daily diet affects our overall health condition and what diseases w ...
NOV 17, 2020
Drug Discovery & Development
Antibiotics Before Age 2 Linked to Childhood Health Conditions
NOV 17, 2020
Antibiotics Before Age 2 Linked to Childhood Health Conditions
Researchers from Mayo Clinic have found a link between children aged two and under taking antibiotics and an increased r ...
Loading Comments...